To reduce the risk that settlements between originator and generic companies are concluded at the expense of consumers, the Commission undertakes to carry out further focused monitoring of settlements that limit or delay the market entry of generic drugs.
Selleks et vähendada originaalravimite ja geneeriliste ravimite tootjate võimalust sõlmida patendikokkuleppeid tarbijate kulul, kavatseb komisjon jätkata geneeriliste ravimite turuletulekut piiravate või pidurdavate kokkulepete süvendatud jälgimist.